In a report released yesterday, Terence Flynn from Morgan Stanley maintained a Hold rating on Editas Medicine (EDIT – Research Report), ...

In a report released today, Joon Lee from Truist Financial maintained a Buy rating on Editas Medicine (EDIT – Research Report). The ...

The request to withdraw the pair of European patents, by lawyers for Nobelists Emmanuelle Charpentier and Jennifer Doudna ... These companies include Editas Medicine, allied with the Broad ...

Now, Editas has sold on some of those same rights ... Ph.D. Alongside fellow Nobel Prize laureate Jennifer Doudna, Ph.D., Charpentier created a type of genetic scissors that can be used to cut ...

Editas will also give up part of a potential ... Prize in Chemistry that was awarded to Emmanuelle Charpentier and Jennifer Doudna. Charpentier is the founder of CRISPR Therapeutics.

The latter team, led by Berkeley’s Jennifer Doudna and Vienna’s Emmanuelle Charpentier ... Broad has already licensed its CRISPR patents for human therapeutics research to Editas Medicine, a Cambridge ...

Editas will also give up part of a potential $50m payment ... basis of the 2020 Nobel Prize in Chemistry that was awarded to Emmanuelle Charpentier and Jennifer Doudna. Charpentier is the founder of ...

UCSB Arts & Lectures and the Cancer Foundation of Santa Barbara host the Nobel Prize–winning biochemist for a talk on CRISPR ...

The technology’s promise can sound like science fiction—it might help us adapt to a radically different climate, or grow ...

Co-hosted by UC Santa Barbara Arts & Lectures and the Cancer Foundation of Santa Barbara, the talk will discuss CRISPR-Cas9 ...